专家视角:难治性皮肤型狼疮的循证治疗策略
皮肤型狼疮(CLE)治疗选择有限且证据等级偏低,难治性病例缺乏共识。本文通过临床案例梳理现有证据,提出难治性CLE的算法化治疗路径,并讨论在研新疗法。
要点
- 难治性CLE常需免疫抑制治疗,但药物选择需权衡风险。
- 系统性狼疮有效的药物对CLE未必有效,证据外推困难。
- SLE临床试验中客观皮肤测量工具的推广有助于明确CLE疗效。
核心结论
- 难治性CLE的治疗需基于现有低等级证据进行算法化决策,并重视免疫抑制治疗的风险选择。
- 需在SLE临床试验中增加客观皮肤测量以明确药物对CLE的疗效并推动新疗法开发。
研究设计与样本
- 本文为专家视角综述,通过临床案例讨论难治性CLE的治疗挑战,梳理现有治疗证据并给出算法化治疗路径。
主要发现
- CLE可表现为多种皮肤损害并严重影响生活质量,有效治疗选择有限且疗效证据等级低。
- 难治性CLE常涉及免疫抑制治疗,存在风险,需审慎选择药物。
- 在系统性狼疮中有效的治疗对皮肤病变可能疗效不足,难以从SLE证据外推。
- SLE临床试验中客观皮肤测量的增加使用对理解CLE药物疗效和新治疗开发是必要的。
关键数值与推荐
- 难治性CLE的治疗决策需考虑免疫抑制治疗的风险与药物选择。
- 应增加SLE临床试验中的客观皮肤测量以评估CLE疗效。
临床怎么用
- 对难治性CLE可参照本文提出的算法化路径选择治疗,并注意免疫抑制治疗的风险管理。
- 不应简单将SLE的系统治疗证据外推至CLE,需关注皮肤病变的特异性疗效证据。
- 关注在研新疗法,其可能不久纳入难治性CLE的治疗方案。
局限性
- CLE有效治疗选项的证据等级普遍偏低,难治性疾病的治疗进展难以达成共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease that can present with a variety of skin manifestations and have a dramatic effect on a patient's quality of life. Effective treatment options for this disease are limited, and the efficacy of these treatments is often supported by low levels of evidence. This makes the treatment of refractory disease especially challenging, as it is difficult to achieve a consensus on the appropriate progression of treatment beyond first- and second-line treatment options. The treatment of refractory CLE often involves some degree of immunosuppression, which carries some risk for patients and requires a thoughtful approach to the selection of medications. Some treatments that have proven to be effective in systemic disease may not be as effective in cutaneous disease, making it difficult to extrapolate from the available evidence on systemic lupus erythematosus (SLE). Ultimately, the increased use of objective skin measurements in SLE clinical trials is necessary to understand drug efficacy in CLE and develop new treatments for this challenging disease. Here, we provide clinical examples of the challenges involved in treating refractory CLE, examine the evidence currently available for treatment options, and provide an algorithmic approach to the treatment of refractory disease based on this evidence. Novel therapies under development for CLE are also discussed, as they may soon be part of the accepted treatment regimen for refractory CLE.
引用
- Borucki R, Werth VP. Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. Arthritis Rheumatol. 2020. PMID: 32776469. doi:10.1002/art.41480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。